Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the psoriasis drug market will grow substantially, reaching $3.3 billion in 2013. According to the new Pharmacor study entitled Psoriasis, premium pricing for biological agents will drive the market.

"The TNF-alpha inhibitors, led by Amgen/Wyeth's Enbrel, will outsell all other drug classes in the next ten years. Another class of biologics that will contribute to the significant growth of the psoriasis market is the T-cell modulators," said Cynthia Mundy, Ph.D., analyst at Decision Resources. "However, although physicians we spoke with are enthusiastic about having several new biological agents available to treat psoriasis patients with moderate to severe disease, they note that none of these agents is effective for all patients. They also cite cost as a major barrier to prescribing these agents."

About Psoriasis

Psoriasis is a chronic skin disease characterized by dry red patches covered with scales. The disease affects an estimated 1-2% of the population -- more than 10 million people -- in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan).

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

More Than 90% of HMO Pharmacy Directors and Physicians View Off-Label Prescribing as an Acceptable Practice in the Management of Arthritis Pain

View Now